Myovant Sciences Stock Price

0.23 (1.57%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 725,222
Bid Price
Ask Price
News (1)
Day High 15.265


52 Week Range


Day Low 14.14
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Myovant Sciences Ltd MYOV NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
0.23 1.57% 14.88 19:48:03
Open Price Low Price High Price Close Price Prev Close
14.41 14.14 15.265 15.12 14.65
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,798 725,222 $ 14.95 $ 10,839,243 - 7.67 - 27.43
Last Trade Time Type Quantity Stock Price Currency
19:59:07 2 $ 15.20 USD


Draw Mode:

Myovant Sciences Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.43B 95.93M 45.55M $ 230.97M $ -124.08M -2.21 -7.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -1.38k 3.00%

more financials information »

Myovant Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MYOV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week13.13515.26512.7313.78729,5731.7513.29%
1 Month12.8515.26511.3312.89617,0312.0315.8%
3 Months8.8615.2658.6611.92683,8376.0267.95%
6 Months12.6415.2657.6711.67753,0592.2417.72%
1 Year19.9727.437.6714.96717,579-5.09-25.49%
3 Years6.8030.89994.1416.10996,5138.08118.82%
5 Years11.9030.89994.1416.05641,4212.9825.04%

Myovant Sciences Description

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Your Recent History
Myovant Sc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now